Cited 0 times in Scipus Cited Count

Harnessing SARS-CoV-2-specific CD8+ T cells to kill target tumor cells for cancer immunotherapy

DC Field Value Language
dc.contributor.authorJung, K-
dc.contributor.authorKo, DH-
dc.contributor.authorJang, JY-
dc.contributor.authorKim, YR-
dc.contributor.authorHeo, JY-
dc.contributor.authorKim, YS-
dc.date.accessioned2024-02-13T23:27:01Z-
dc.date.available2024-02-13T23:27:01Z-
dc.date.issued2024-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/32181-
dc.language.isoen-
dc.subject.MESHCD8-Positive T-Lymphocytes-
dc.subject.MESHCOVID-19-
dc.subject.MESHHumans-
dc.subject.MESHImmunotherapy-
dc.subject.MESHNeoplasms-
dc.subject.MESHSARS-CoV-2-
dc.titleHarnessing SARS-CoV-2-specific CD8+ T cells to kill target tumor cells for cancer immunotherapy-
dc.typeArticle-
dc.identifier.pmid37856250-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10794008-
dc.contributor.affiliatedAuthorJung, K-
dc.contributor.affiliatedAuthorKim, YR-
dc.contributor.affiliatedAuthorHeo, JY-
dc.type.localJournal Papers-
dc.identifier.doi10.1002/cac2.12497-
dc.citation.titleCancer communications (London, England)-
dc.citation.volume44-
dc.citation.number1-
dc.citation.date2024-
dc.citation.startPage173-
dc.citation.endPage177-
dc.identifier.bibliographicCitationCancer communications (London, England), 44(1). : 173-177, 2024-
dc.identifier.eissn2523-3548-
dc.relation.journalidJ025233548-
Appears in Collections:
Journal Papers > Hospital > Clinical Trial Center
Journal Papers > School of Medicine / Graduate School of Medicine > Infectious Diseases
Files in This Item:
37856250.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse